Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (608)	9/18/2002 10:25:38 AM
From: Icebrg	Read Replies (2) \| Respond to of 2240

IDM Announces the Nomination of Michael T. Lotze to Its Scientific Advisory Board Wednesday September 18, 2:41 am ET PARIS--(BUSINESS WIRE)--Sept. 18, 2002--Immuno-Designed Molecules, S.A. (IDM), a leading European biopharmaceutical company in the field of immunotherapy, announces the nomination of Michael T. Lotze, M.D. to its Scientific Advisory Board. Dr. Lotze is Professor of Surgery, Molecular Genetics and Biochemistry at the University of Pittsburgh Cancer Institute and Director of Translational Research in its Institute of Molecular Medicine. Prior to this, he was Chief of Surgical Oncology and Codirector of Biologic Therapeutics and Gene Therapy for ten years at the University of Pittsburgh. This followed a period where he was Senior Investigator at the National Cancer Institute for twelve years. In these two former positions, he initiated novel cytokine, cellular and gene therapies for patients with cancer. Between 1999 and 2001 he held the position of Vice President of Discovery Research at SmithKline Beecham and after the merger creating GlaxoSmithKline, he assumed the role of VP of High Throughput Biology creating the first group within the pharmaceutical industry in charge of accelerating drug discovery from genomic research. Since then he has returned to the Faculty at the University of Pittsburgh where he initiated the creation of PBI, the first integrated biological therapeutic company developing biomarkers and surrogates for patients with chronic inflammatory diseases. He has published over 5 books and 450 articles to date. "We are extremely proud to welcome Michael Lotze to IDM. He is a world renowned scientist in the field of oncology," declared Jean-Loup Romet-Lemonne, President and CEO of IDM, "and he has a very pragmatic approach to the benefits of cellular immunotherapy and to delivering scientific results in immunology to cancer patient therapy." "The promise of cellular therapy has yet to be fully realized but will ultimately become the mainstay of cancer treatment. I believe that IDM's clinical development and scientific team is among the premier groups in the world approaching this area and has the ability to deliver successful therapies to patients with cancer. In the field of cellular immunotherapy, IDM is leader in this fast moving field and is achieving regular milestones to make cell therapy a reality. I appreciate IDM's high scientific level approach to therapeutics and, above all, dedication to cancer patients." commented Michael Lotze. IDM -- The Immunogenics Company® IDM is a leading biopharmaceutical company developing a new family of immunotherapy products called Cell Drugs to fight cancer and other life-threatening diseases. IDM applies its proprietary technologies to selectively isolate, engineer, expand and activate specific cell populations which are involved in therapeutic vaccination. The Company's products are designed to boost the immune system, destroy residual tumor cells, and immunize patients to prevent tumor recurrence. IDM's most advanced product is in Phase III for the treatment of ovarian cancer.